MindWalk revenue up 21%, losses widen, cash down
MindWalk Holdings Corp. (HYFT), a Bio-Native AI drug discovery company, reported higher revenue but deeper losses for the three months ended July 31, 2026.
Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
MindWalk Holdings Corp. (HYFT), a Bio-Native AI drug discovery company, reported higher revenue but deeper losses for the three months ended July 31, 2026. Revenue from continuing operations was $3.8 million, up 21.3% from the prior-year quarter, driven mainly by higher project revenue. Gross profit rose to $2.2 million with a gross margin of 59%, compared with 48% a year earlier, as cost of sales remained relatively flat.
Operating expenses increased to $8.4 million from $5.7 million, largely due to higher sales and marketing, general and administrative, and share-based compensation, resulting in a larger net loss from continuing operations of $6.1 million versus $4.1 million. Cash and restricted cash declined to $7.8 million from $11.5 million at April 30, 2026. Management states that existing cash is not sufficient to fund operations for at least one year, raising substantial doubt about the company’s ability to continue as a going concern without additional financing. A previously identified material weakness in internal control over financial reporting related to complex technical accounting remains unremediated, although remediation efforts are ongoing.
Positive
- Revenue grew 21.3% year over year to $3.8 million, reflecting stronger project activity.
- Gross margin improved to 59% from 48%, with gross profit rising to $2.2 million, indicating more profitable mix or efficiency in delivery.
- The company reports progress on an AI-driven internal asset pipeline and HYFT-based platforms (LensAI, ReefIQ), positioning it within several high-growth AI drug discovery and informatics markets.
Negative
- Net loss from continuing operations widened to $6.1 million from $4.1 million, as operating expenses climbed to $8.4 million.
- Going-concern risk is explicitly disclosed: current cash of $7.8 million is not expected to fund operations for at least one year without additional financing.
- Cash and restricted cash declined from $11.5 million to $7.8 million in three months, reflecting ongoing negative operating cash flow of $4.0 million.
- A previously identified material weakness in internal control over financial reporting remains unremediated as of July 31, 2026.
